Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment

Abstract

BackgroundDespite the availability of effective therapies, asthma remains a source of significant morbidity and use of health care resources. The central research question of the ACCURATE trial is whether maximal doses of (combination) therapy should be used for long periods in an attempt to achieve complete control of all features of asthma. An additional question is whether patients and society value the potential incremental benefit, if any, sufficiently to concur with such a treatment approach. We assessed patient preferences and cost-effectiveness of three treatment strategies aimed at achieving different levels of clinical control:1. sufficiently controlled asthma2. strictly controlled asthma3. strictly controlled asthma based on exhaled nitric oxide as an additional disease markerDesign720 Patients with mild to moderate persistent asthma from general practices with a practice nurse, age 18-50 yr, daily treatment with inhaled corticosteroids (more then 3 months usage of inhaled corticosteroids in the previous year), will be identified via patient registries of general practices in the Leiden, Nijmegen, and Amsterdam areas in The Netherlands. The design is a 12-month cluster-randomised parallel trial with 40 general practices in each of the three arms. The patients will visit the general practice at baseline, 3, 6, 9, and 12 months. At each planned and unplanned visit to the general practice treatment will be adjusted with support of an internet-based asthma monitoring system supervised by a central coordinating specialist nurse. Patient preferences and utilities will be assessed by questionnaire and interview. Data on asthma control, treatment step, adherence to treatment, utilities and costs will be obtained every 3 months and at each unplanned visit. Differences in societal costs (medication, other (health) care and productivity) will be compared to differences in the number of limited activity days and in quality adjusted life years (Dutch EQ5D, SF6D, e-TTO, VAS). This is the first study to assess patient preferences and cost-effectiveness of asthma treatment strategies driven by different target levels of asthma control.Trial registrationNetherlands Trial Register (NTR): NTR1756

Longitudinal outcomes of different asthma phenotypes in primary care, an observational study

“…We also included FeNO as a variable in our analyses as it is now available in primary care and is shown to be cost-effective. 22 We also included the variable pack years smoked in the cluster analysis. The amount of pack years smoked highly influences respiratory disease progression.…”

Symptom- and fraction of exhaled nitric oxide–driven strategies for asthma control: A cluster-randomized trial in primary care

“…A detailed description of study procedures, sample size calculation, and measurements has been published elsewhere. 22 …”

Protocolled practice nurse-led care for children with asthma in primary care: protocol for a cluster randomised trial

“…However, this method could result in the selection of children who do not use the medication, despite the prescription. Nevertheless, a registered diagnosis, also referred to as ‘physician-diagnosed asthma’ has been used as an inclusion criterium in other trials 11 36 37. For our study, we considered asthma to be present in the children, when they were prescribed an ICS ( > one time) or salbutamol or terbutaline ( > two times) in the previous year or had only one prescription of salbutamol or terbutaline in the previous year and a registered ICPC code for asthma (R96) or R29.02 ‘Prikkelbare luchtwegen’ (bronchial spasm) .…”